The global GLP-1/GIPR Dual Peptide Agonist market was valued at US$ 30218 million in 2025 and is anticipated to reach US$ 64372 million by 2032, at a CAGR of 11.3% from 2026 to 2032.

GLP-1/GIPR Dual Peptide Agonist Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on GLP-1/GIPR Dual Peptide Agonist competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global GLP-1/GIPR Dual Peptide Agonist production reached approximately 156.36 M Units, with an average global market price of around 193.26 USD per Unit.

A GLP-1/GIPR Dual Peptide Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIPR Dual Peptide Agonist product in the world.

GLP-1/GIPR Dual Peptide Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.

The upstream raw materials for GLP-1/GIPR Dual Peptide Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of GLP-1/GIPR Dual Peptide Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

The North American market for GLP-1/GIPR Dual Peptide Agonist is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for GLP-1/GIPR Dual Peptide Agonist is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of GLP-1/GIPR Dual Peptide Agonist include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global GLP-1/GIPR Dual Peptide Agonist market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding GLP-1/GIPR Dual Peptide Agonist. The GLP-1/GIPR Dual Peptide Agonist market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global GLP-1/GIPR Dual Peptide Agonist market comprehensively. Regional market sizes by Type, by Application, by Receptor Agonist Properties, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist GLP-1/GIPR Dual Peptide Agonist manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of GLP-1/GIPR Dual Peptide Agonist Market Report

Report Metric	Details
Report Name	GLP-1/GIPR Dual Peptide Agonist Market
Accounted market size in 2025	US$ 30218 million
Forecasted market size in 2032	US$ 64372 million
CAGR	11.3%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Injection Oral Administration
Segment by Receptor Agonist Properties	Balanced Biased
Segment by Medicinal Efficacy	Long-acting Short-acting
by Application	Diabetes Obesity Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Receptor Agonist Properties, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for GLP-1/GIPR Dual Peptide Agonist manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines GLP-1/GIPR Dual Peptide Agonist sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is GLP-1/GIPR Dual Peptide Agonist Market growing?

Ans: The GLP-1/GIPR Dual Peptide Agonist Market witnessing a CAGR of 11.3% during the forecast period 2026-2032.

What is the GLP-1/GIPR Dual Peptide Agonist Market size in 2032?

Ans: The GLP-1/GIPR Dual Peptide Agonist Market size in 2032 will be US$ 64372 million.

Who are the main players in the GLP-1/GIPR Dual Peptide Agonist Market report?

Ans: The main players in the GLP-1/GIPR Dual Peptide Agonist Market are Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma

What are the Application segmentation covered in the GLP-1/GIPR Dual Peptide Agonist Market report?

Ans: The Applications covered in the GLP-1/GIPR Dual Peptide Agonist Market report are Diabetes, Obesity, Others

What are the Type segmentation covered in the GLP-1/GIPR Dual Peptide Agonist Market report?

Ans: The Types covered in the GLP-1/GIPR Dual Peptide Agonist Market report are Injection, Oral Administration

1 GLP-1/GIPR Dual Peptide Agonist Market Overview

1.1 Product Definition

1.2 GLP-1/GIPR Dual Peptide Agonist by Type

1.2.1 Global GLP-1/GIPR Dual Peptide Agonist Market Value by Type: 2025 vs 2032

1.2.2 Injection

1.2.3 Oral Administration

1.3 GLP-1/GIPR Dual Peptide Agonist by Receptor Agonist Properties

1.3.1 Global GLP-1/GIPR Dual Peptide Agonist Market Value by Receptor Agonist Properties: 2025 vs 2032

1.3.2 Balanced

1.3.3 Biased

1.4 GLP-1/GIPR Dual Peptide Agonist by Medicinal Efficacy

1.4.1 Global GLP-1/GIPR Dual Peptide Agonist Market Value by Medicinal Efficacy: 2025 vs 2032

1.4.2 Long-acting

1.4.3 Short-acting

1.5 GLP-1/GIPR Dual Peptide Agonist by Application

1.5.1 Global GLP-1/GIPR Dual Peptide Agonist Market Value by Application: 2025 vs 2032

1.5.2 Diabetes

1.5.3 Obesity

1.5.4 Others

1.6 Global GLP-1/GIPR Dual Peptide Agonist Market Size Estimates and Forecasts

1.6.1 Global GLP-1/GIPR Dual Peptide Agonist Revenue 2021–2032

1.6.2 Global GLP-1/GIPR Dual Peptide Agonist Sales 2021–2032

1.6.3 Global GLP-1/GIPR Dual Peptide Agonist Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 GLP-1/GIPR Dual Peptide Agonist Market Competition by Manufacturers

2.1 Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Manufacturers (2021–2026)

2.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Manufacturers (2021–2026)

2.3 Global GLP-1/GIPR Dual Peptide Agonist Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of GLP-1/GIPR Dual Peptide Agonist, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Product Types and Applications

2.7 Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Date of Entry into the Industry

2.8 Global GLP-1/GIPR Dual Peptide Agonist Market Competitive Situation and Trends

2.8.1 Global GLP-1/GIPR Dual Peptide Agonist Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global GLP-1/GIPR Dual Peptide Agonist Players Market Share by Revenue

2.8.3 Global GLP-1/GIPR Dual Peptide Agonist Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global GLP-1/GIPR Dual Peptide Agonist Market Scenario by Region

3.1 Global GLP-1/GIPR Dual Peptide Agonist Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global GLP-1/GIPR Dual Peptide Agonist Sales by Region: 2021–2032

3.2.1 Global GLP-1/GIPR Dual Peptide Agonist Sales by Region: 2021–2026

3.2.2 Global GLP-1/GIPR Dual Peptide Agonist Sales by Region: 2027–2032

3.3 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Region: 2021–2032

3.3.1 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Region: 2021–2026

3.3.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Region: 2027–2032

3.4 North America GLP-1/GIPR Dual Peptide Agonist Market Facts & Figures by Country

3.4.1 North America GLP-1/GIPR Dual Peptide Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America GLP-1/GIPR Dual Peptide Agonist Sales by Country (2021–2032)

3.4.3 North America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe GLP-1/GIPR Dual Peptide Agonist Market Facts & Figures by Country

3.5.1 Europe GLP-1/GIPR Dual Peptide Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe GLP-1/GIPR Dual Peptide Agonist Sales by Country (2021–2032)

3.5.3 Europe GLP-1/GIPR Dual Peptide Agonist Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific GLP-1/GIPR Dual Peptide Agonist Market Facts & Figures by Region

3.6.1 Asia Pacific GLP-1/GIPR Dual Peptide Agonist Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific GLP-1/GIPR Dual Peptide Agonist Sales by Region (2021–2032)

3.6.3 Asia Pacific GLP-1/GIPR Dual Peptide Agonist Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America GLP-1/GIPR Dual Peptide Agonist Market Facts & Figures by Country

3.7.1 Latin America GLP-1/GIPR Dual Peptide Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America GLP-1/GIPR Dual Peptide Agonist Sales by Country (2021–2032)

3.7.3 Latin America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Market Facts & Figures by Country

3.8.1 Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Sales by Country (2021–2032)

3.8.3 Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global GLP-1/GIPR Dual Peptide Agonist Sales by Type (2021–2032)

4.1.1 Global GLP-1/GIPR Dual Peptide Agonist Sales by Type (2021–2026)

4.1.2 Global GLP-1/GIPR Dual Peptide Agonist Sales by Type (2027–2032)

4.1.3 Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Type (2021–2032)

4.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Type (2021–2032)

4.2.1 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Type (2021–2026)

4.2.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Type (2027–2032)

4.2.3 Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Type (2021–2032)

4.3 Global GLP-1/GIPR Dual Peptide Agonist Price by Type (2021–2032)

5 Segment by Application

5.1 Global GLP-1/GIPR Dual Peptide Agonist Sales by Application (2021–2032)

5.1.1 Global GLP-1/GIPR Dual Peptide Agonist Sales by Application (2021–2026)

5.1.2 Global GLP-1/GIPR Dual Peptide Agonist Sales by Application (2027–2032)

5.1.3 Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Application (2021–2032)

5.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Application (2021–2032)

5.2.1 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Application (2021–2026)

5.2.2 Global GLP-1/GIPR Dual Peptide Agonist Revenue by Application (2027–2032)

5.2.3 Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Application (2021–2032)

5.3 Global GLP-1/GIPR Dual Peptide Agonist Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Eli Lilly

6.1.1 Eli Lilly Company Information

6.1.2 Eli Lilly Description and Business Overview

6.1.3 Eli Lilly GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Eli Lilly GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.1.5 Eli Lilly Recent Developments/Updates

6.2 Roche

6.2.1 Roche Company Information

6.2.2 Roche Description and Business Overview

6.2.3 Roche GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Roche GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.2.5 Roche Recent Developments/Updates

6.3 Viking Therapeutics

6.3.1 Viking Therapeutics Company Information

6.3.2 Viking Therapeutics Description and Business Overview

6.3.3 Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.3.5 Viking Therapeutics Recent Developments/Updates

6.4 Ascletis Pharma

6.4.1 Ascletis Pharma Company Information

6.4.2 Ascletis Pharma Description and Business Overview

6.4.3 Ascletis Pharma GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Ascletis Pharma GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.4.5 Ascletis Pharma Recent Developments/Updates

6.5 Jiangsu Hengrui Medicine

6.5.1 Jiangsu Hengrui Medicine Company Information

6.5.2 Jiangsu Hengrui Medicine Description and Business Overview

6.5.3 Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates

6.6 East China Pharmaceutical

6.6.1 East China Pharmaceutical Company Information

6.6.2 East China Pharmaceutical Description and Business Overview

6.6.3 East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.6.5 East China Pharmaceutical Recent Developments/Updates

6.7 Tonghua Dongbao Pharmaceutical

6.7.1 Tonghua Dongbao Pharmaceutical Company Information

6.7.2 Tonghua Dongbao Pharmaceutical Description and Business Overview

6.7.3 Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.7.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates

6.8 Lepu Medical Technology

6.8.1 Lepu Medical Technology Company Information

6.8.2 Lepu Medical Technology Description and Business Overview

6.8.3 Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.8.5 Lepu Medical Technology Recent Developments/Updates

6.9 Hansoh Pharma

6.9.1 Hansoh Pharma Company Information

6.9.2 Hansoh Pharma Description and Business Overview

6.9.3 Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Product Portfolio

6.9.5 Hansoh Pharma Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 GLP-1/GIPR Dual Peptide Agonist Industry Chain Analysis

7.2 GLP-1/GIPR Dual Peptide Agonist Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 GLP-1/GIPR Dual Peptide Agonist Production Mode & Process Analysis

7.4 GLP-1/GIPR Dual Peptide Agonist Sales and Marketing

7.4.1 GLP-1/GIPR Dual Peptide Agonist Sales Channels

7.4.2 GLP-1/GIPR Dual Peptide Agonist Distributors

7.5 GLP-1/GIPR Dual Peptide Agonist Customer Analysis

8 GLP-1/GIPR Dual Peptide Agonist Market Dynamics

8.1 GLP-1/GIPR Dual Peptide Agonist Industry Trends

8.2 GLP-1/GIPR Dual Peptide Agonist Market Drivers

8.3 GLP-1/GIPR Dual Peptide Agonist Market Challenges

8.4 GLP-1/GIPR Dual Peptide Agonist Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

List of Tables

Table 1. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Receptor Agonist Properties (US$ Million), 2025 vs 2032

Table 3. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Medicinal Efficacy (US$ Million), 2025 vs 2032

Table 4. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global GLP-1/GIPR Dual Peptide Agonist Market Competitive Situation by Manufacturers in 2025

Table 6. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Manufacturers (2021–2026)

Table 8. Global GLP-1/GIPR Dual Peptide Agonist Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global GLP-1/GIPR Dual Peptide Agonist Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market GLP-1/GIPR Dual Peptide Agonist Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of GLP-1/GIPR Dual Peptide Agonist, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Product Types and Applications

Table 14. Global Key Manufacturers of GLP-1/GIPR Dual Peptide Agonist, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global GLP-1/GIPR Dual Peptide Agonist Companies by Tier (Tier 1, Tier 2, Tier 3), based on GLP-1/GIPR Dual Peptide Agonist Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global GLP-1/GIPR Dual Peptide Agonist Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global GLP-1/GIPR Dual Peptide Agonist Sales by Region (K Units), 2021–2026

Table 20. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Region (2021–2026)

Table 21. Global GLP-1/GIPR Dual Peptide Agonist Sales by Region (K Units), 2027–2032

Table 22. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Region (2027–2032)

Table 23. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Region (US$ Million), 2021–2026

Table 24. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Region (2021–2026)

Table 25. Global GLP-1/GIPR Dual Peptide Agonist Revenue by Region (US$ Million), 2027–2032

Table 26. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Region (2027–2032)

Table 27. North America GLP-1/GIPR Dual Peptide Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2021–2026

Table 29. North America GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2027–2032

Table 30. North America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2021–2026

Table 31. North America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2027–2032

Table 32. Europe GLP-1/GIPR Dual Peptide Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2021–2026

Table 34. Europe GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2027–2032

Table 35. Europe GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2021–2026

Table 36. Europe GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America GLP-1/GIPR Dual Peptide Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2021–2026

Table 44. Latin America GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2027–2032

Table 45. Latin America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Revenue by Country (US$ Million), 2027–2032

Table 52. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units) by Type (2021–2026)

Table 53. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units) by Type (2027–2032)

Table 54. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Type (2021–2026)

Table 55. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Type (2027–2032)

Table 56. Global GLP-1/GIPR Dual Peptide Agonist Revenue (US$ Million) by Type (2021–2026)

Table 57. Global GLP-1/GIPR Dual Peptide Agonist Revenue (US$ Million) by Type (2027–2032)

Table 58. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Type (2021–2026)

Table 59. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Type (2027–2032)

Table 60. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Type (2021–2026)

Table 61. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Type (2027–2032)

Table 62. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units) by Application (2021–2026)

Table 63. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units) by Application (2027–2032)

Table 64. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Application (2021–2026)

Table 65. Global GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Application (2027–2032)

Table 66. Global GLP-1/GIPR Dual Peptide Agonist Revenue (US$ Million) by Application (2021–2026)

Table 67. Global GLP-1/GIPR Dual Peptide Agonist Revenue (US$ Million) by Application (2027–2032)

Table 68. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Application (2021–2026)

Table 69. Global GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Application (2027–2032)

Table 70. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Application (2021–2026)

Table 71. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Application (2027–2032)

Table 72. Eli Lilly Company Information

Table 73. Eli Lilly Description and Business Overview

Table 74. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Product

Table 76. Eli Lilly Recent Developments/Updates

Table 77. Roche Company Information

Table 78. Roche Description and Business Overview

Table 79. Roche GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Roche GLP-1/GIPR Dual Peptide Agonist Product

Table 81. Roche Recent Developments/Updates

Table 82. Viking Therapeutics Company Information

Table 83. Viking Therapeutics Description and Business Overview

Table 84. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Product

Table 86. Viking Therapeutics Recent Developments/Updates

Table 87. Ascletis Pharma Company Information

Table 88. Ascletis Pharma Description and Business Overview

Table 89. Ascletis Pharma GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. Ascletis Pharma GLP-1/GIPR Dual Peptide Agonist Product

Table 91. Ascletis Pharma Recent Developments/Updates

Table 92. Jiangsu Hengrui Medicine Company Information

Table 93. Jiangsu Hengrui Medicine Description and Business Overview

Table 94. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Product

Table 96. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 97. East China Pharmaceutical Company Information

Table 98. East China Pharmaceutical Description and Business Overview

Table 99. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product

Table 101. East China Pharmaceutical Recent Developments/Updates

Table 102. Tonghua Dongbao Pharmaceutical Company Information

Table 103. Tonghua Dongbao Pharmaceutical Description and Business Overview

Table 104. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product

Table 106. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 107. Lepu Medical Technology Company Information

Table 108. Lepu Medical Technology Description and Business Overview

Table 109. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 110. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Product

Table 111. Lepu Medical Technology Recent Developments/Updates

Table 112. Hansoh Pharma Company Information

Table 113. Hansoh Pharma Description and Business Overview

Table 114. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 115. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Product

Table 116. Hansoh Pharma Recent Developments/Updates

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. GLP-1/GIPR Dual Peptide Agonist Distributors List

Table 120. GLP-1/GIPR Dual Peptide Agonist Customers List

Table 121. GLP-1/GIPR Dual Peptide Agonist Market Trends

Table 122. GLP-1/GIPR Dual Peptide Agonist Market Drivers

Table 123. GLP-1/GIPR Dual Peptide Agonist Market Challenges

Table 124. GLP-1/GIPR Dual Peptide Agonist Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Product Picture of GLP-1/GIPR Dual Peptide Agonist

Figure 2. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Type (US$ Million), 2021–2032

Figure 3. Global GLP-1/GIPR Dual Peptide Agonist Market Share by Type: 2025 & 2032

Figure 4. Injection Product Picture

Figure 5. Oral Administration Product Picture

Figure 6. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Receptor Agonist Properties (US$ Million), 2021–2032

Figure 7. Global GLP-1/GIPR Dual Peptide Agonist Market Share by Receptor Agonist Properties: 2025 vs 2032

Figure 8. Balanced Product Picture

Figure 9. Biased Product Picture

Figure 10. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Medicinal Efficacy (US$ Million), 2021–2032

Figure 11. Global GLP-1/GIPR Dual Peptide Agonist Market Share by Medicinal Efficacy: 2025 vs 2032

Figure 12. Long-acting Product Picture

Figure 13. Short-acting Product Picture

Figure 14. Global GLP-1/GIPR Dual Peptide Agonist Market Value by Application (US$ Million), 2021–2032

Figure 15. Global GLP-1/GIPR Dual Peptide Agonist Market Share by Application: 2025 & 2032

Figure 16. Diabetes

Figure 17. Obesity

Figure 18. Others

Figure 19. Global GLP-1/GIPR Dual Peptide Agonist Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 20. Global GLP-1/GIPR Dual Peptide Agonist Market Size (US$ Million), 2021–2032

Figure 21. Global GLP-1/GIPR Dual Peptide Agonist Sales (K Units), 2021–2032

Figure 22. Global GLP-1/GIPR Dual Peptide Agonist Average Price (US$/Unit), 2021–2032

Figure 23. GLP-1/GIPR Dual Peptide Agonist Report Years Considered

Figure 24. GLP-1/GIPR Dual Peptide Agonist Sales Share by Manufacturers in 2025

Figure 25. Global GLP-1/GIPR Dual Peptide Agonist Revenue Share by Manufacturers in 2025

Figure 26. Top 5 and Top 10 Global GLP-1/GIPR Dual Peptide Agonist Players: Market Share by Revenue in GLP-1/GIPR Dual Peptide Agonist in 2025

Figure 27. GLP-1/GIPR Dual Peptide Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 28. Global GLP-1/GIPR Dual Peptide Agonist Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 29. North America GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Country (2021–2032)

Figure 30. North America GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Country (2021–2032)

Figure 31. United States GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Canada GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Europe GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Country (2021–2032)

Figure 34. Europe GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Country (2021–2032)

Figure 35. Germany GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. France GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. U.K. GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Italy GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. Russia GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Region (2021–2032)

Figure 41. Asia Pacific GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Region (2021–2032)

Figure 42. China GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Japan GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. South Korea GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. India GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Australia GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. China Taiwan GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Southeast Asia GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Latin America GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Country (2021–2032)

Figure 50. Latin America GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Country (2021–2032)

Figure 51. Mexico GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Brazil GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Argentina GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Colombia GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Sales Market Share by Country (2021–2032)

Figure 56. Middle East and Africa GLP-1/GIPR Dual Peptide Agonist Revenue Market Share by Country (2021–2032)

Figure 57. Turkey GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Saudi Arabia GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. UAE GLP-1/GIPR Dual Peptide Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Global Sales Market Share of GLP-1/GIPR Dual Peptide Agonist by Type (2021–2032)

Figure 61. Global Revenue Market Share of GLP-1/GIPR Dual Peptide Agonist by Type (2021–2032)

Figure 62. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Type (2021–2032)

Figure 63. Global Sales Market Share of GLP-1/GIPR Dual Peptide Agonist by Application (2021–2032)

Figure 64. Global Revenue Market Share of GLP-1/GIPR Dual Peptide Agonist by Application (2021–2032)

Figure 65. Global GLP-1/GIPR Dual Peptide Agonist Price (US$/Unit) by Application (2021–2032)

Figure 66. GLP-1/GIPR Dual Peptide Agonist Value Chain

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions